Combining Camu-Camu prebiotics and anti-programmed cell death protein-1 to improve gut microbiome and clinical outcomes for patients with non-small cell lung cancer

结合 Camu-Camu 益生元和抗程序性细胞死亡蛋白-1，改善非小细胞肺癌患者的肠道微生物组和临床结果

• 批准号: 466902
• 负责人: Lynn Matthew J
• 金额: $ 1.27万
• 依托单位: Universit de Montral
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466902&lang=en
• 关键词: Anti-Pd-1; Avatar Mice Models; Cancer Immunology; Cancer-Microbiome; Gut Microbiome; Immune Checkpoint Inhibitors; Lung Cancer Therapy; Metagenomics; Non-Small Cell Lung Cancer; Prebiotics

Lung cancer is the most diagnosed cancer and the leading cause of cancer deaths in Canada. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers, but primary response rates to immune checkpoint inhibitors (ICI), specifically anti-programmed-

肺癌是加拿大最常见的癌症，也是癌症死亡的主要原因。非小细胞肺癌（NSCLC）占肺癌的85%，但对免疫检查点抑制剂（ICI），特别是抗程序性非小细胞肺癌（NSCLC）的主要反应率，